BioCentury | Mar 19, 2012
Clinical News

Technetium-99m-EC-G: SPA received

...Cell Point received an SPA from FDA for a Phase III trial to evaluate IV technetium-99m-EC-G...
...timeline for the trial start was not disclosed. Cell Point LLC , Centennial, Colo. Product: Technetium-99m-EC-G...
...Business: Diagnostic Molecular target: NA Description: Single photon emission computed tomography (SPECT) cancer imaging agent 99m-Tc-EC-G...
BioCentury | May 9, 2011
Regulation

Looking for better conditions

Endocyte Inc. 's plans for EC145 in ovarian cancer illustrate the divide between FDA and EMA on early approval of drugs based on progression-free survival. The company plans to seek conditional approval in the EU...
Items per page:
1 - 2 of 2